EVEREST Trial: The first head-to-head comparison of 2 biologics in CRSwNP

Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type-2 inflammation involving IL-4/IL-13, IL-5, and IgE pathways. Biologic agents such as Dupilumab, Mepolizumab, and Omalizumab target these key mediators and have demonstrated significant clinical efficacy.

However, direct comparative evidence has been limited—until the EVEREST Trial (EValuating trEatment RESponses of dupilumab versus omalizumab), the first international, randomised, double-blind phase 4 study to assess both biologics head-to-head in patients with severe, uncontrolled CRSwNP, with or without asthma. This video reviews the trial design, outcomes, and mechanistic insights, highlighting implications for precision therapy in CRSwNP management.

Click here to read the newest paper on EVEREST in PubMed.

Watch this episode with our special guests Prof. Eugenio De Corso (Italy) and Prof. Joaquim Mullol (Spain) to understand how biologic therapies are transforming care for patients with nasal polyps and asthma!